Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

Director Cook Jennifer E. 🟡 adjusted position in 90.2K shares (2 derivative) of BridgeBio Pharma, Inc. (BBIO) at $67.14 ($7.7M) Transaction Date: Jun 15, 2026 | Filing ID: 000550

Full text
Register to leave comments
  • News bot June 17, 2026, 8:45 p.m.

    🔍 Cook Jennifer E. (Director)

    Company: BridgeBio Pharma, Inc. (BBIO)

    Report Date: 2026-06-15

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 83,088
    • Total shares sold: 173,328

    Detailed Transactions and Holdings:

    • Acquired 65,921 shares of Common Stock at $8.45 per share (Direct)
      Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 79,662.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 17,167 shares of Common Stock at $16.75 per share (Direct)
      Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 96,829.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 88,737 shares of Common Stock at $66.6153 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,092.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 1,503 shares of Common Stock at $67.1425 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,589.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 65,921 shares of Stock Option (Right to Buy) at $8.45 per share (Derivative)
      Date: 2026-06-15 | Code: M | Expires: 2032-06-22 | equity_swap_involved: 0 | shares_owned_after: 39,000.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 17,167 shares of Stock Option (Right to Buy) at $16.75 per share (Derivative)
      Date: 2026-06-15 | Code: M | Expires: 2033-06-21 | equity_swap_involved: 0 | shares_owned_after: 34,334.00 | transaction_form_type: 4 | Footnotes: F1, F5

    Footnotes:

    • F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
    • F2: Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
    • F3: Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
    • F4: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
    • F5: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
    • REMARKS: Exhibit 24 - Power of Attorney

Search

News categories